John Najim

    John Najim
    Vice President, Manufacturing and Process Development
    John Najim joined Proteon in 2009 and has served as our Vice President, Manufacturing and Process Development since 2015, prior to which he was the Senior Director of Manufacturing and Process Development from 2011 until 2014 and Director of Manufacturing from 2009 until 2011. Prior to joining Proteon, Mr. Najim served as Associate Director of Manufacturing at Dyax Corporation from 2004 to 2009. Prior to that, Mr. Najim spent six years, from 1998 to 2004, in a variety of roles at Johnson and Matthey, Genzyme Transgenics and Northeastern University, including manufacturing, process development, and research development. Mr. Najim holds a B.S. in Biochemistry from Merrimack College and an M.B.A. from the Graduate School of Business at Bentley University.

    Daniel Gottlieb

      Daniel P. Gottlieb
      Vice President, Corporate Development
      Daniel Gottlieb joined Proteon in 2007 and has served as our Vice President, Marketing and Business Development since 2013, prior to which he was the Senior Director of Marketing and Business Development from 2010 until 2013 and Director of Marketing and Business Development from 2007 until 2010. Prior to joining Proteon, Mr. Gottlieb served as Strategic Marketing Manager of Endovascular Products at Abbott Vascular from 2006 to 2007. Prior to that, Mr. Gottlieb spent seven years, from 1999 to 2006, at Guidant Corporation in a variety of roles, including marketing and market research, strategic planning, and business development and corporate venture investing as part of Guidant’s Compass Group. Mr. Gottlieb holds a B.A. from the University of Pennsylvania and an M.B.A. from the Tuck School of Business at Dartmouth College.

      Pamela Gustafson

        Pamela Gustafson
        Vice President, Clinical Research
        Pamela Gustafson joined Proteon in 2006 and has served as our Vice President, Clinical Research since 2015, prior to which she was the Senior Director of Clinical Research from 2012 until 2014 and Director of Clinical Research from 2006 until 2012. Prior to joining Proteon, Ms. Gustafson served as Director of Clinical Operations at Trine Pharmaceuticals from 2002 to 2006. Prior to that, Ms. Gustafson worked as a Project Manager at AAI International from 1999 until 2002, LeukoSite, Inc. from 1998 until 1999, and PAREXEL International from 1996 until 1998. Prior to PAREXEL, Ms. Gustafson spent ten years, from 1986 to 1996, in drug development positions at Alkermes, Seragen, Genzyme Corporation, and the Massachusetts Eye and Ear Infirmary. Ms. Gustafson holds a B.A. from Wheaton College and an M.P.H. from Boston University. Ms. Gustafson is also certified as a Project Management Professional.

        Scott Toner

          Scott Toner
          Senior Vice President, Commercial
          Scott Toner joined Proteon in 2015 as our Senior Vice President, Marketing. Prior to joining Proteon, from 2014 to 2015, Mr. Toner served as the VP Marketing and Sales of OPKO Health’s Renal Division. From 2013 to 2014, he served as a consultant to companies in the biotechnology industry and from 2011 to 2012 served as Senior Director, Marketing of Reata Pharmaceuticals. Prior to that, from 2007 to 2010, Mr. Toner served as Executive Director of Marketing with AMAG Pharmaceuticals. From 1985 to 2007, Mr. Toner held various roles within the domestic and international divisions of Abbott Laboratories, concentrating primarily on the nephrology and critical care therapeutic spaces. Mr. Toner holds a B.A. from Ithaca College and an M.B.A. from Drexel University.

          F. Nicholas Franano, M.D.

            F. Nicholas Franano, M.D.
            Founder, Proteon Therapeutics, Inc.
            F. Nicholas Franano, M.D., has served as a member of our board of directors since 2006. Dr. Franano is currently President and Chief Executive Officer of Flow Forward Medical, Inc., and Metactive Medical, Inc., two companies developing cardiovascular medical devices, where he has served since 2014. Prior to this, Dr. Franano was founder, President and Chief Executive Officer of Novita Therapeutics, a medical device incubator company. Dr. Franano founded Proteon, and served as our Chief Executive Officer from 2001 to 2006, and after that as our Chief Scientific Officer from 2006 to 2009. Dr. Franano received an M.D. and an M.A. in biomedical research from Washington University, St. Louis, and a B.S. in cell biology from the University of Kansas. He completed a residency in diagnostic radiology and a fellowship in interventional radiology at the Johns Hopkins Hospital. Prior to founding Proteon, Dr. Franano maintained a clinical practice in interventional radiology from 2000 through 2005.

            Todd Foley

              Todd Foley
              Managing Director, MPM Capital
              Todd Foley has served as a member of our board of directors since 2012. Since 1999, Mr. Foley has been a managing director with MPM Capital, a venture capital firm, working from its Boston office. Prior to joining MPM, Mr. Foley worked in business development at Genentech and in management consulting with Arthur D. Little. Mr. Foley currently serves as a member of the board of directors of Aires Pharmaceuticals, Inc., Celladon Corporation, Chiasma, Inc. and Selexys Pharmaceuticals Corporation. Mr. Foley received a B.S. in chemistry from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.

              Timothy Noyes

                Timothy P. Noyes
                President and Chief Executive Officer
                Timothy Noyes joined Proteon in 2006 as our President and Chief Executive Officer and has also been a member of our board of directors since joining the company. From 2002 to 2006, Mr. Noyes served as Chief Operating Officer of Trine Pharmaceuticals, Inc., a biopharmaceutical company. Before joining Trine, Mr. Noyes held several management positions with GelTex Pharmaceuticals from 1996 to 2001, prior to its acquisition by Genzyme Corporation. After the acquisition, from 2001 to 2002, he held the position of President, Renal Division and President, GelTex Pharmaceuticals. Prior to GelTex, he worked for several years at Merck & Co. across multiple roles in its hypertension and heart failure group and managed care division, and on its Vasotec and Prilosec products. Mr. Noyes received an A.B. from Harvard College and an M.B.A. from Harvard Business School.